Drug details

Besponsa (inotuzumab ozogamicin injection)

type of Antineoplastics, Other

Besponsa (inotuzumab ozogamicin) for injection is a CD22-directed antibody-drug conjugate (ADC) indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• upper stomach pain,
• fever,
• easy bruising,
• pale skin,
• shortness of breath,
• yellowing of the skin or eyes (jaundice),
• fainting,
• weakness,
• cough,
• mouth sores,
• rapid weight gain,
• feeling cold,
• fast or pounding heartbeats,
• skin sores,
• swollen gums,
• cold or flu symptoms,
• coughing up blood, and
• vomit that looks like coffee grounds
• bleeding gums,
• abnormal vaginal bleeding,
• headache with chest pain and severe dizziness,
• itchiness,
• blood in your urine or stools,
• feverish,
• swelling in your arms or legs,
• painful swelling in your midsection,

The following drugs are related to Besponsa, either as a replacement or used together:

• Actiq (fentanyl citrate)
• Libtayo (cemiplimab-rwlc injection)
• Femring (estradiol acetate)
• EstroGel (estradiol gel)
• Etopophos (etoposide phosphate)
• VePesid (etoposide)
• Nivestym (filgrastim-aafi injection)
• Lumoxiti (moxetumomab pasudotox-tdfk for injection)
• Poteligeo (mogamulizumab-kpkc injection)